Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting.Molecular oncology · 2026
   Article
2. Current and future treatment of rheumatoid arthritis.Journal of rheumatic diseases · 2026
   Review
3. Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Article
4. A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma.Journal of nanobiotechnology · 2024
   Article
5. A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma.Clinical and translational medicine · 2024
   Article
6. Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment.Heliyon · 2024
   Article
7. Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze.HemaSphere · 2024
   Article
8. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.Cancers · 2023
   Review
9. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.OncoTargets and therapy · 2023
   Review
10. Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.Biomedicines · 2022
    Article
11. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
12. Loncastuximab Tesirine: First Approval.Drugs · 2021
    Review
13. Clinical immunity and medical cost of COVID-19 patients under grey relational mathematical model.Results in physics · 2021
    Article
14. The use of tafasitamab in diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2021
    Review
15. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.Frontiers in immunology · 2021
    Review
16. Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes.International journal of molecular sciences · 2020
    Review
17. Tafasitamab: First Approval.Drugs · 2020
    Review
18. Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.Veterinary pathology · 2020
    Article
19. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.Drugs in context · 2019
    Review

Corrections and comments

• Comment on
  Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as